Last Updated : September 21, 2023
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Draft Recommendations
Biologics in Plaque Psoriasis
Streamlined Drug Class Review
Draft recommendations posted for stakeholder feedback: September 21, 2023
End of feedback period: October 5, 2023,
Recommendations and Reasons (draft)
Responses to Questions from the Drug Programs (draft)
Updated Recommendations for Biologics in Plaque Psoriasis (draft)
rivaroxaban (N/A)
Therapeutic Area: Venous thromboembolic events (VTE)
Draft recommendations posted for stakeholder feedback: September 21, 2023
End of feedback period: October 6, 2023,
Draft Recommendation and Reasons
Draft Responses to Questions from the Drug Programs
setmelanotide (Imcivree)
Therapeutic Area: Bardet-Biedl syndrome
Draft recommendations posted for stakeholder feedback: September 14, 2023
End of feedback period: September 28, 2023
Draft Recommendation
dupilumab (Dupixent)
Therapeutic Area: Atopic dermatitis, pediatrics
Draft recommendations posted for stakeholder feedback: September 14, 2023
End of feedback period: September 28, 2023
Draft Recommendation
Open Calls for Patient and Clinician Input
Emergency Department Overcrowding in Canada: An Update
End of feedback period: September, 2023
NovoTTF-200A ( Optune )
End of feedback period: January, 2024
2024 Watch List: Care for Children and Youth With Medical Complexity
End of feedback period: January, 2024
Therapeutic Area
Therapeutic Area:
Crohn’s disease and Ulcerative Colitis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Seizures associated with Tuberous Sclerosis Complex (TSC)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Endogenous Cushing’s syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Locally advanced or metastatic NSCLC (first line)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Dravet Syndrome (DS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Lennox-Gastaut Syndrome (LGS)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area:
Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Last Updated : September 21, 2023